Genmab (ADR) (GMAB)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
Something off on this page? Send us feedback.
Develops antibody medicines and platforms, earning royalties from partner-marketed products while co-commercializing EPKINLY/TEPKINLY and independently selling Tivdak in Europe and Japan. A Copenhagen-based global organization is building wholly owned oncology programs, while revenue and pipeline progress depend on partners and clinical, regulatory, manufacturing, and launch execution.
Develops antibody medicines from Copenhagen using proprietary bispecific, hexamerization, and antibody-drug conjugate technologies. Revenue combines royalties from partner-marketed medicines with product sales, milestones, collaboration payments, and license fees.
Partner products include DARZALEX, Kesimpta, RYBREVANT, TECVAYLI, TALVEY, and TEPEZZA. EPKINLY/TEPKINLY is co-commercialized with AbbVie, while Tivdak's European and Japanese launches established an independent commercial channel across a business spanning North America, Europe, and Asia-Pacific.
Wholly owned oncology programs include Rina-S and petosemtamab, supported by technologies and teams added through ProfoundBio and Merus. The operating model relies on partners' sales and development execution for royalties, and on clinical, regulatory, manufacturing, launch, acquisition-integration, and financing execution for proprietary medicines.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 22, 2026 | Cowen & Co. | Upgrade | ||
| Jul 22, 2026 | New Street | Target | Target: — | Target: $43 |
| Jul 22, 2026 | TD Cowen | Upgrade | ||
| May 27, 2026 | Truist Financial | Target | Target: $48 | Target: $40 |
| Apr 30, 2026 | H.C. Wainwright | Target | Target: $39 | Target: $38 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.50B · Total debt $5.27B · Total assets $12.52B · Shareholders' equity $5.96B
- Revenue
- $1.16B
- Operating income
- $407.0M
- Net income
- $303.0M
No dividends on record.
| Institutions | 31.85% | 204.85M ADS | |
|---|---|---|---|
| 306 holders · as of Jun 30, 2026 | |||
| Other | 68.15% | 438.23M ADS | |
| remainder | |||
643.08M ADS (1 ADS = 0 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Paradigm Biocapital Advisors LPInstitution | 4.08% | 13.13M ADS · 13.13M ADS | as of Jun 30, 2026 |
Orbis Allan Gray LtdInstitution | 3.54% | 11.37M ADS · 11.37M ADS | as of Jun 30, 2026 |
AllianceBernstein L.P.Institution | 2.69% | 8.64M ADS · 8.64M ADS | as of Jun 30, 2026 |
Deerfield Management Company, L.P. (Series C)Institution | 2.14% | 6.87M ADS · 6.87M ADS | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 1.76% | 5.65M ADS · 5.65M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
FRα-targeted ADC rival in gynecologic oncology
- Regeneron
CD20×CD3 bispecific rival in relapsed/refractory lymphoma
- Eli Lilly
Dual rival in FRα ADCs and EGFR-targeted head-and-neck cancer
- Bristol-Myers Squibb
Cell-therapy and checkpoint rival across lymphoma and cervical cancer
- Merck
Checkpoint-inhibitor rival in cervical and head-and-neck cancer
- AstraZeneca (ADR)
Late-stage FRα ADC rival in gynecologic oncology
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genmab (ADR) | $34.94 | +0.71% | $21.30B | 27.3 | 26.7 | 5.2 | +24.9% |
| AbbVie | $265.87 | +0.53% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Regeneron | $804.59 | +0.80% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Eli Lilly | $1,166.02 | +0.10% | $1.10T | 39.1 | 28.5 | 13.8 | +47.7% |
| Bristol-Myers Squibb | $62.69 | +0.11% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Merck | $152.17 | +1.79% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| AstraZeneca (ADR) | $168.41 | +0.18% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Median | 32.2 | 16.7 | 5.4 | +8.3% |